Mesoblast Ltd has released a press release.
Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- Third Quarter Results Presentation
- MSB Q3 Financial Results and Operational Highlights
- S&P DJI Announces March 2022 Quarterly Rebalance
- Second Quarter Results Presentation
- Ulcerative Colitis & Crohns Results Presented at ECCO
Later from Mesoblast
- Reinstatement to Quotation
- US$45 Million Private Placement to Major Shareholders
- Preliminary Final Report
- MSB Annual Financial Results and Operational Highlights
- Submits New Information to FDA IND File for SR-aGVHD
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast